{"id":724828,"date":"2023-01-20T16:33:47","date_gmt":"2023-01-20T21:33:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-amends-20-million-convertible-note-under-collaboration-agreement-with-its-partner-cytovia-therapeutics\/"},"modified":"2023-01-20T16:33:47","modified_gmt":"2023-01-20T21:33:47","slug":"cellectis-amends-20-million-convertible-note-under-collaboration-agreement-with-its-partner-cytovia-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-amends-20-million-convertible-note-under-collaboration-agreement-with-its-partner-cytovia-therapeutics\/","title":{"rendered":"Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics"},"content":{"rendered":"
\n

NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) — Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it has amended certain financial terms of the $20 million convertible note issued by its partner, Cytovia Therapeutics, LLC (\u201cCytovia\u201d) in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement between Cellectis and Cytovia.<\/p>\n

The amended and restated note provides for automatic conversion into common stock of Cytovia in the case of certain fundamental transactions pursuant to which Cytovia becomes a public reporting company and for conversion at Cellectis\u2019 option in connection with certain financing transactions, upon a company sale and at final maturity. In each case such conversion is subject to a 9.9% ownership cap, with the balance issuable in the form of pre-funded warrants. Among other changes, the amended and restated note increased the applicable interest rate of the note to 10% per annum, subject to a 10% step up upon the occurrence and continuation of an event of default, provided for the repayment of 50% of the outstanding amount on April 30, 2023 and extended the final maturity date for the repayment of the remaining outstanding amount to June 30, 2023.<\/p>\n

\n About Cellectis<\/strong>\u00a0
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN\u00ae, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis\u2019 headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).\u00a0<\/p>\n

\n About Cytovia Therapeutics<\/strong>\n <\/p>\n

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK\u2122 bispecific antibody platforms. The company is developing three types of iNK cells: unedited iNK cells, TALEN\u00ae gene-edited iNK cells with improved function and persistence, and TALEN\u00ae gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia\u2019s proprietary Flex-NK\u2122 technology.<\/p>\n

These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Headquartered in\u00a0Aventura, FL., Cytovia has research and development laboratories in\u00a0Natick, MA. The company\u2019s own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the\u00a0Hebrew University of\u00a0Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the\u00a0University of California San Francisco\u00a0(UCSF). Cytovia has a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities in\u00a0Greater China.\u00a0<\/p>\n

Find out more at\u00a0www.cytoviatx.com<\/a>\u00a0and follow us on\u00a0Facebook<\/a>,\u00a0Twitter<\/a>,\u00a0LinkedIn<\/a>,\u00a0YouTube<\/a>, and\u00a0Instagram<\/a>.<\/p>\n

\n Forward-looking Statements<\/strong>\u00a0
This press release contains \u201cforward-looking\u201d statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cintend\u201d, \u201cexpect,\u201d \u201cplan,\u201d \u201cscheduled,\u201d \u201ccould\u201d and \u201cwill,\u201d or the negative of these and similar expressions. These forward-looking statements, which are based on our management\u2019s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the conversion of the convertible note. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development and market conditions. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Cellectis makes with the Securities and Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.\u00a0<\/p>\n

\n For further information on Cellectis, please contact:<\/strong>\u202f\u202f\u00a0<\/p>\n

\n Media contact:<\/strong>\u202f\u202f\u00a0
Pascalyne Wilson,\u202fDirector,\u202fCommunications,\u202f+33 (0)7 76 99 14 33, media@cellectis.com<\/u><\/a> \u00a0<\/p>\n

\n Investor Relation contact:<\/strong>\u202f\u202f\u00a0
Arthur Stril, Chief Business Officer, +1 (347) 809 5980,\u00a0 investors@cellectis.com<\/u><\/a>\u202f\u202f\u00a0
Ashley R. Robinson, LifeSci Advisors, +1 617\u202f430 7577\u00a0<\/p>\n

\n For further information on Cytovia, please contact:<\/strong>\n <\/p>\n

\n Investor Relations contact:<\/strong>
\n
Anna Baran-Djokovic, VP, Investor Relations & Capital Markets, +1 305 615 9162, anna@cytoviatx.com<\/a><\/p>\n

\n Attachment<\/strong>\n <\/p>\n